Home › Cancro del polmone non a piccole cellule › California › Mountain View
Studi clinici su Cancro del polmone non a piccole cellule a Mountain View, CA
21 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Mountain View e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
In reclutamentoFase 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · a 5 mi di distanza
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · a 5 mi di distanza
- Stanford Cancer Institute Palo Alto, Palo Alto · a 5 mi di distanza
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
In reclutamentoFase 3
- Stanford University, Stanford · a 5 mi di distanza
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
In reclutamentoFase 2
- Stanford Cancer Institute, Stanford · a 5 mi di distanza
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
In reclutamentoStudio osservazionale
- Stanford University, Palo Alto · a 5 mi di distanza
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
In reclutamentoFase 2
- Stanford Cancer Institute, Stanford · a 5 mi di distanza
- Stanford Hospital and Clinics, Stanford · a 5 mi di distanza
- Stanford Hospital Investigational Drug Services, Stanford · a 5 mi di distanza
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Stanford Cancer Center, Palo Alto · a 5 mi di distanza
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Stanford Cancer Institute, Stanford · a 5 mi di distanza
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
In reclutamentoFase 1/2
- Stanford University Medical Center - Neurology, Stanford · a 5 mi di distanza
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Palo Alto Medical Foundation Research Center, Palo Alto · a 5 mi di distanza
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
In reclutamentoFase 1/2
- Stanford Cancer Institute, Stanford · a 5 mi di distanza
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
In reclutamentoFase 1/2
- Stanford University Medical Center, Stanford · a 5 mi di distanza
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
In reclutamentoFase 1
- Stanford University Medical Center, Palo Alto · a 5 mi di distanza
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
In reclutamentoFase 1
- Stanford University, Palo Alto · a 5 mi di distanza
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
In reclutamentoFase 1/2
- Stanford University - Stanford Cancer Institute, Stanford · a 5 mi di distanza
A Study of LY4175408 in Participants With Advanced Cancer
In reclutamentoFase 1
- Stanford Medicine Cancer Center, Stanford · a 5 mi di distanza
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
In reclutamentoFase 1/2
- Stanford University, Stanford · a 5 mi di distanza
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
In reclutamentoFase 1/2
- Stanford Women's Cancer Center, Palo Alto · a 5 mi di distanza
Engagement of Veterans With Lung Cancer
In reclutamento
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · a 5 mi di distanza
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Stanford · a 5 mi di distanza
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
In reclutamentoFase 1
- Stanford University, Stanford · a 5 mi di distanza
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Altri studi a Mountain View
- Cancro (tutti i tipi)40 studi
- Cancro al seno26 studi
- Cancro metastatico25 studi
- Leucemia mieloide acuta19 studi
- Cancro ovarico19 studi
- Disturbo dello spettro autistico17 studi
- Cancro ai polmoni17 studi
- Cancro alla prostata15 studi
- Insufficienza cardiaca15 studi
- Autismo13 studi
- Leucemia linfoblastica acuta13 studi
- Cancro colorettale13 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.